Abstract
The object of this work was to study the long-term effects of the hydrazinophthalazines [hydralazine (Apresoline) or dihydralazine (Nepresol)] using our own clinical studies (38 patients treated with dihydralazine) and a review of the literature. Their short-term effects are well known but there is less information available on their long-term effects (2, 8). It is generally accepted that the pharmacological effects of the two commercially available hydrazinophthalazines are very similar.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Boxenbaum HG, Riegelman S (1974) Determination of isoniazide and metabolites in biological fluides. J Pharm Sci 63: 1191
Chatterjee K, Parmley WW, Massie B, Greenberg B, Werner J, Klausner S, Norman A (1976) Oral hydralazine therapy for chronic refractory heart failure. Circulation 54: 879
Convert G (1978) Etude prognostique des cardiomyopathies primitives non obstructives. Med Dissertation, Lyon University
Eitchett DH, Marin Neto JA, Oakley CM, Goodwin JF (1979) Hydralazine in the management of left ventricular failure. Am J Cardiol 44: 303–309
Massie B, Ports T, Chatterjee K, Parmley W, Ostland J, O’Young J, Haughom F (1981) Longterm vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63: 269–278
Massie B, Kramer B, Gaughom F (1981) Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation 63: 658–664
Mathey DM, Hanrath P, Polste J, Witte G, Montz R, Bleifield W (1981) Short term and long term effects of oral hydralazine on left ventricular pump function and renal haemodynamics in chronic left heart failure. In: Rutishauser W (ed) The place of vasodilators in the long-term treatment of intractable heart failure. Hans Huber, Bern Stuttgart Vienna
Morand P, Lavigne G, Masson D, Latour F, Alison D (1979) Traitement de l’insuffisance cardiaque chronique sévère par la dihydralazine. Arch Mal Coeur 3: 268
Packer M, Meller J, Medina N, Gorlin R, Herman MV (1980) Dose requirements of hydralazine in patients with severe chronic congestive heart failure. Am J Cardiol 45: 655
Perry HM (1973) Late toxicity to hydralazine ressembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54: 56
Wechsler B, Brion NO, Colan C, Ximines H, Godeau P (1979) Lupus érythémateux induit par la dihydralazine. Nouv Presse Méd 45: 8
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Morand, P., Lavigne, G. (1983). The Long-Term Effects of Dihydralazine and Hydralazine on Intractable Cardiac Failure. In: Just, H., Bussmann, WD. (eds) Vasodilators in Chronic Heart Failure. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-68605-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-68605-4_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-68607-8
Online ISBN: 978-3-642-68605-4
eBook Packages: Springer Book Archive